Betawise · Investor brief · 2026
The intelligence layer for continuous glucose monitoring.
CGMs are becoming as common as smartwatches. Betawise turns their data into weekly, clinically grounded action for patients — and a standardized, billable summary for the clinicians who care for them.
The data revolution in diabetes stalled at the last mile.
A CGM produces ~4,000 readings every two weeks. Most people see a specialist for minutes a few times a year, and device apps stop at charts and averages. The result: better sensors, stubborn outcomes.
Four curves just crossed.
FDA cleared the first OTC CGMs in 2024, opening the category to tens of millions of people with Type 2 diabetes and prediabetes who are not on insulin — and who have no endocrinologist.
International consensus targets (2019) and ADA Standards of Care now center CGM metrics, giving us a shared, objective outcome to coach toward and report on.
Frontier models can explain data with empathy at a cost of cents per conversation. We estimate under $1 per active member per month in model costs.
CGM interpretation and remote patient monitoring have established CPT codes, so clinics have a reason to adopt tools that make CGM review fast and standardized.
From raw readings to one thing to do this week.
Ingest
Dexcom OAuth, Clarity and LibreView exports, mg/dL or mmol/L. Analysis runs on-device.
Measure
Consensus metrics, GMI, CV, Glycemia Risk Index, AGP — deterministic and auditable.
Prioritize
Pattern engine ranks safety first, then sizes each opportunity in points of time in range.
Act
Weekly focus, an AI coach, progress tracking, and a one-page clinic report for the care team.
A weekly focus and coach that knows their patterns. Commitments and progress tracking turn insight into habit.
A consensus-format summary (AGP, targets, flagged patterns, patient questions) that makes a 15-minute visit count.
Population-level time-in-range and GRI movement — an objective, continuous outcome metric instead of a quarterly A1C.
We measure what matters to the person, not engagement.
Our north-star metric is time in range gained per member, with time below range as a safety constraint that can never get worse. Every 10 points of time in range is associated with roughly a 0.8-point lower A1C and substantially lower risk of eye and kidney complications.
Free for people. Paid by the organizations that save money when they do better.
| Channel | Customer | How we're paid | Why they buy |
|---|---|---|---|
| Consumer | People with diabetes | Free core; optional premium (coach, history, family sharing) | Mission, distribution, and the data flywheel |
| Clinics | Endocrinology & primary care | Per-provider SaaS | Faster, standardized CGM review supporting existing interpretation and RPM workflows |
| Payers & employers | Health plans, self-insured employers | Per-member-per-month, with outcomes-based upside | Diabetes is among their largest cost drivers; TIR is a measurable outcome |
| Device partners | CGM makers, OTC retail | White-label licensing | Onboarding and retention for new OTC users with no clinician |
Pricing to be validated in pilots. Revenue figures are intentionally omitted until pilot data exist.
The only option built for every CGM user, between every visit.
| Device apps | Virtual diabetes programs | Clinic data platforms | Metabolic wellness apps | Betawise | |
|---|---|---|---|---|---|
| Type 1 and Type 2 | ✓ | Mostly T2 | ✓ | Non-diabetic | ✓ |
| Tells you what to do this week | — | ✓ | — | ✓ | ✓ |
| Consensus-standard clinical report | ✓ | Varies | ✓ | — | ✓ |
| Device-agnostic | — | Varies | ✓ | Varies | ✓ |
| Free for individuals | ✓ | Through employer or plan | Through clinic | Subscription | ✓ free core |
| Marginal cost per member | Low | High (human-led) | Low | Low | Low (AI-first) |
Trust is the moat in healthcare AI.
Metrics and patterns are computed by tested, auditable code. The language model explains — it never calculates or invents a number. This is what lets clinicians trust the report.
No dosing advice, server-side prompts, deterministic emergency and crisis triage, and data minimization by default (the AI sees summary statistics only).
Every patient who brings a Betawise report into an appointment introduces the product to a care team. That makes clinics a low-cost acquisition channel and the natural first paying customer.
With explicit opt-in, de-identified "focus → result" data teaches us which weekly focuses actually move time in range for which people.
Built to ship responsibly, and to scale into regulated care.
Today Betawise is designed as an educational, non-dosing tool whose logic is transparent to the user and their clinician. Data stays on-device for consumers. B2B deployments will run on HIPAA-ready infrastructure under BAAs. Any future feature that recommends treatment changes would go through the appropriate FDA pathway first.
Regulatory positioning should be confirmed with qualified FDA counsel before commercial launch.
From beta to the standard of care.
Now · Beta
- Consensus analytics, GRI, AGP
- Pattern engine & weekly focus
- AI coach with guardrails
- Clinic report, Dexcom + CSV
Next · Pilots
- Accounts with encrypted sync
- Abbott & Apple Health integrations
- 2–3 clinic pilots, 1 employer pilot
- 90-day outcomes study (TIR, TBR)
Then · Scale
- Clinician dashboard & EHR export
- Meal, activity & medication context
- Spanish-language coach
- Payer contracts on outcomes
Where we are.
- Working product: analytics engine with automated tests, AI coach, clinic report
- Beta users: [#] · Weekly active: [%]
- Clinic / partner LOIs: [names or #]
- [Founder — role, lived experience, background]
- [Clinical advisor — endocrinologist / CDCES]
- [Technical lead]